Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Neuroendocrine 2Neoplasms 1Multiple Myeloma 1Carcinoma 1Carcinoid Tumor 1

Interventions

Octreotide 5Everolimus 5pasireotide 3lanreotide 2Bevacizumab 2surufatinib 1pembrolizumab 1ganitumab 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1azaspirane 1arginyllysine 1TKM-080301 1Sunitinib 1Rose Bengal 1Random Allocation 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1CX 3543 1Biological Therapy 1Biological Factors 12-Methoxyestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoid Tumor × azaspirane × Clear all
NCT00388063 2007-12-21

Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Callisto Pharmaceuticals

Phase 2 Completed
55 enrolled
Endocrine

Carcinoid Tumor, Carcinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡